Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial

被引：1
|
作者：
Patel, K.
Gu, Y.
Hicks, K. O.
Atwell, G. J.
Denny, W. A.
Jameson, M. B.
Rischin, D.
Pegram, M.
Gutheil, J. C.
Wilson, W. R.
机构：
[1] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[2] Waikato Hosp, Hamilton, New Zealand
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Proacta Inc, San Diego, CA USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70268-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
263
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors
    Jameson, M. B.
    Rischin, D.
    Pegram, M.
    Gutheil, J. C.
    Patterson, A.
    Denny, W.
    Wilson, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug administered on a weekly schedule in patients with solid tumors
    Melink, T. J.
    Jameson, M. B.
    McKeage, M. J.
    Gutheil, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] The role of bystander effects in the an hypoxia-activated prodrug PR-104
    Foehrenbacher, Annika
    Patel, Kashyap
    Abbattista, Maria R.
    Guise, Chris P.
    Secomb, Timothy W.
    Wilson, William R.
    Hicks, Kevin O.
    FRONTIERS IN ONCOLOGY, 2013, 3
  • [4] Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program
    Houghton, Peter J.
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Phelps, Doris
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Wozniak, Amy W.
    Gu, Yongchuan
    Wilson, William R.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2011, 57 (03) : 443 - 453
  • [5] Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104
    Benito, Juliana
    Shi, Yuexi
    Szymanska, Barbara
    Carol, Hernan
    Bohem, Ingrid
    Lu, Hongbo
    Konoplev, Sergej
    Fang, Wendy
    Kornblau, Steven M.
    Zweidler-McKay, Patrick
    Wilson, William
    Campana, Dario
    Borthakur, Gautam
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Shpall, Elizabeth J.
    Thomas, Deborah A.
    Jordan, Craig T.
    Lock, Richard B.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2010, 116 (21) : 379 - 380
  • [6] Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
    Benito, Juliana
    Shi, Yuexi
    Szymanska, Barbara
    Carol, Hernan
    Boehm, Ingrid
    Lu, Hongbo
    Konoplev, Sergej
    Fang, Wendy
    Zweidler-McKay, Patrick A.
    Campana, Dario
    Borthakur, Gautam
    Bueso-Ramos, Carlos
    Shpall, Elizabeth
    Thomas, Deborah A.
    Jordan, Craig T.
    Kantarjian, Hagop
    Wilson, William R.
    Lock, Richard
    Andreeff, Michael
    Konopleva, Marina
    PLOS ONE, 2011, 6 (08):
  • [7] Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models
    Singleton, R. S.
    Pullen, S. M.
    Ferry, D. M.
    Guise, C. P.
    Patterson, A. V.
    Wilson, W. R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 151 - 151
  • [8] A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
    Jameson, Michael B.
    Rischin, Danny
    Pegram, Mark
    Gutheil, John
    Patterson, Adam V.
    Denny, William A.
    Wilson, William R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 791 - 801
  • [9] A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
    Michael B. Jameson
    Danny Rischin
    Mark Pegram
    John Gutheil
    Adam V. Patterson
    William A. Denny
    William R. Wilson
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 791 - 801
  • [10] Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice
    Gu, Yongchuan
    Guise, Christopher P.
    Patel, Kashyap
    Abbattista, Maria R.
    Lie, Jie
    Sun, Xueying
    Atwell, Graham J.
    Boyd, Maruta
    Patterson, Adam V.
    Wilson, William R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 543 - 555
12345